Bioglutide (NA-931)
NA-931
NA-931, also branded Bioglutide, is an experimental weight loss pill that is still in clinical trials and is not approved anywhere. The company reported large weight loss in a 13 week trial of about 125 people, but those results were shared only at conferences and in news reports, not in a peer reviewed journal, and the reported numbers shifted between meetings. Claims about saving muscle and having fewer side effects have no published data behind them.
Where the evidence stands
What it is
NA-931 is an experimental drug for obesity made by Biomed Industries of San Jose, California. It is also branded as Bioglutide.[1][2]
The trial registry calls it an oral peptide taken once a day as a capsule.[3] Its exact structure has not been made public, so we cannot list a formula or sequence.
Plain truth: very little reliable information about this drug is public. We found trial registry entries, a short conference abstract, company press releases and news reports of company presentations, but no full peer reviewed study.[3][4]
- Name
- Bioglutide (NA-931) (NA-931)
- Other names
- Bioglutide, NA931
- Type
- Peptide
What it does in the body
NA-931 does not occur in nature. The company says it is a peptide that switches on four hormone receptors, GLP-1, GIP, glucagon and IGF-1, the first three of which help control appetite and blood sugar after meals. None of this has been confirmed in published, independent research.[2][3]
This is the biology, area by area. A change measured in the body, like a higher blood level, does not always mean a person feels a benefit. The claims check below covers that.
Fat and appetite
Measured in peopleIn a 13 week placebo controlled trial of about 125 adults with obesity or overweight, the company reported average weight loss of up to about 14 to 15 percent at the top dose, rising with dose, and said up to 72 percent on the drug lost at least 12 percent of body weight versus 2 percent on placebo.[4][2] These results are not peer reviewed.
Gut and digestion
Measured in peopleStomach side effects were the most common complaint. One company summary put nausea and vomiting at about 7 percent and diarrhea at about 6 percent of treated people.[4] A later news report gave diarrhea as 8.1 percent on the drug versus 3.2 percent on placebo, with nausea and vomiting similar on drug and placebo.[2]
How it works
The company says NA-931 turns on four hormone receptors at once. Receptors are switches on cells that hormones flip.
- The four targets named are GLP-1, GIP, glucagon and IGF-1 receptors.[2][3]
- Drugs that act on GLP-1, such as semaglutide and tirzepatide, are already used for weight loss.[5]
- Adding IGF-1 is unusual. The company reported no muscle loss in its phase 2 trial, but it did not say how muscle was measured.[2][4]
This mechanism comes from the company and has not been checked by outside scientists.
What the research shows
We keep animal and human evidence apart. A result in animals is a reason to study something in people, not proof that it works in people.
Animal and lab studies
One short mouse study, shared only as a conference abstract
- We found no peer reviewed animal studies of NA-931, only a short company abstract in an outlet that does not meet our source standards.
- We found no published animal toxicity or long term safety studies.
Limit: This is a short company abstract, not a full published study, and mouse results often do not carry over to people.
Human studies
Small company trials, results not yet peer reviewed
- Phase 1: a first in human safety trial enrolled 74 people with obesity or type 2 diabetes and was completed in September 2024. We found no published results.[7]
- Phase 2 design: a placebo controlled trial of a daily capsule in adults with obesity, or overweight plus at least one weight related health problem. It ran for 13 weeks and finished in April 2025. The registry lists 126 people, and its listed outcomes are weight change and side effects.[3]
- First report, July 2025: at an endocrine meeting, the company reported average weight loss of up to 13.8 percent at 13 weeks, which it said was 12.4 percent more than placebo, with nausea and vomiting in about 7 percent and diarrhea in about 6 percent of treated people.[4]
- Second report, September 2025: at a diabetes meeting, the company reported average weight loss of up to 14.8 percent at 13 weeks, about 13.2 points more than placebo, rising with dose.[2]
- Share of big responders: up to 72 percent of people on the drug lost at least 12 percent of body weight, versus 2 percent on placebo, according to the company.[2][4]
- Side effects: most were described as mild. In the September report, nausea and vomiting occurred at similar rates on drug and placebo, and diarrhea was more common on the drug (8.1 percent versus 3.2 percent).[2]
- Not reported: dropout rates, serious side effects, blood sugar and cholesterol results were not included in the news coverage or company releases we found.[2][4]
- A phase 2 trial testing NA-931 alone or with tirzepatide, planned for about 224 people over 48 weeks, was listed with a planned start in August 2026 and was not yet recruiting at its last update.[6]
Limit: All human results so far come from the company itself, the reported numbers changed between meetings, and nothing has passed independent peer review.
Claims check
The most common claims about this compound, and what studies actually found. Verdicts rate the evidence, not whether you should use it.
Causes major weight loss
Mixed resultsIn a 13 week placebo controlled trial of about 125 adults with obesity or overweight plus a weight related health problem, the company first reported average weight loss of up to 13.8 percent at the top dose, about 12.4 points more than placebo.[4] Two months later a news report of a company talk gave up to 14.8 percent, about 13.2 points more than placebo, with up to 72 percent losing at least 12 percent of their weight versus 2 percent on placebo.[2] These results have not been peer reviewed, and the trial was short.[3]
Burns fat without losing muscle
Not testedThe company stated that no muscle loss was seen in its phase 2 trial, but it gave no method or numbers.[4][2] The trial's registry entry lists weight and side effects as its outcomes and no body composition or muscle measure.[3] No published study has measured muscle or lean mass on this drug.
A pill that works as well as weight loss shots
Not testedThe company says its weight loss was comparable to leading injectable drugs.[1] No trial has compared it head to head with any injection. A trial pairing it with tirzepatide was listed as not yet recruiting, with a planned start in August 2026.[6]
Fewer side effects than other GLP-1 drugs
Not testedThe company described its side effects as mostly mild and short lived.[4] In its own trial, nausea and vomiting were common but similar on drug and placebo, while diarrhea was more frequent on the drug (8.1 percent versus 3.2 percent).[2] No head to head comparison with other drugs exists.
Improves blood sugar, cholesterol and liver fat
Not testedNo peer reviewed study in animals or people has reported effects on blood sugar, cholesterol or liver fat, and news reports of the human trial did not include these results.[2]
Known risks and side effects
- Unknown long term safety. The longest reported trial lasted only 13 weeks, so effects over months or years are unknown.[3]
- Stomach side effects. Nausea and vomiting were common in the company's trial, and diarrhea affected 8.1 percent on the drug versus 3.2 percent on placebo.[2]
- Products sold online are not the trial drug. Anything sold online as Bioglutide is not the company's trial product. FDA warns that weight loss drugs sold as research use only have unknown quality.[5]
- Banned in sport. Because it is not approved anywhere, it likely falls under WADA's S0 class, which bans any unapproved drug at all times.[8]
Regulatory status
Today: NA-931 is not approved by FDA or any other agency. It is an experimental drug studied in registered clinical trials, and its next listed trial had not started recruiting as of the registry's last update in March 2026.[3][6]
- First in human phase 1 trial begins.[7]
- Phase 2 trial in adults with obesity begins.[3]
- Phase 2 trial is completed.[3]
- Company presents first phase 2 results at the ENDO 2025 meeting.[4]
- Company presents phase 2 results at the EASD diabetes meeting.[2]
- Planned start of a phase 2 trial combining NA-931 with tirzepatide.[6]
Sources
- Longevity.Technology. First in class oral drug NA-931 shows strong phase 2 obesity results. September 10, 2025. News report
- Pharmaceutical Technology. EASD 2025: NA-931 in obese patients. September 18, 2025. News report
- ClinicalTrials.gov. Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition. NCT06564753. NCT06564753
- Biomed Industries, Inc. Biomed Industries unveils promising phase 2 results of NA-931, first oral quadruple agonist for obesity, at ENDO 2025. Press release via EIN Presswire. July 17, 2025. Company release
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026. FDA safety page
- ClinicalTrials.gov. A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women. NCT06732245. NCT06732245
- ClinicalTrials.gov. Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus. NCT06615700. NCT06615700
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. Effective January 1, 2026. WADA 2026 Prohibited List
This page is educational information only. It is not medical advice and does not replace care from a licensed medical provider. Do not use this page to decide whether to take any substance. Talk to a licensed medical provider first.
Found an error or a newer study? We correct pages fast.
Report a correction →